ي الغرض من إطار عمل إجراءات المراقبة القائمة عىل األحداث هو أن به
ن
تستعي السلطات والوكاالت المسؤولة عن المراقبة
ُ واالستجابة. كما
تيب إرشال تعىل سبيل المثال؛ هذ...ه الوثيقة ألصحاب المصلحة
ي
ُ
ُعد بمثابة ك
ا عاما ي
إطار استخدام
ي
الذين يرغبون ف ن
نهج "صحة واحدة" متعدد القطاعات لتنفيذ المراقبة القائمة عىل األحداث . و للقيام بذلك، تشتمل الوثيقة عىل فصول وملحق
ن مرتبطة ويمكن
للمستخدمي تغييها وتحديثها
بناء عىل احتياجاتهم الخاصة.
ُعد هذه
الت ي وت نسخة منقحة من النسخة األصلية "إطار عمل المراقبة القائمة عىل األحداث"
عام
ي
ن صدرت
ف 2018 .و ال ينسخ إطار
العمل هذا أو يحل محل أي مواد أخرى متاحة حاليا في ما يتعلق بمج ال المراقبة القائمة عىل األحداث أن
ن ؛ وبدال من ذلك، ينبعي
يستند إطار العمل إل الوثائق الموجودة سابقا ذات الصلة أو مرتبطة وأن يكون تيب
ُ
ك ا إرشاديا عملي ا لتنفيذ المراقبة القائمة عىل
األحداث أفريقيا.
ي
ن
ف ويتوافق إطار العمل ك لمنظمة الصحة العالمية
المشي
ي
هذا مع الطبعة الثالثة من التقييم الخارج فيما يتعلق
ر بالمؤشات التالية: تعزيز
ي عىل كشف األحداث ذات األهمية للصحة العامة واألمن الصح أنظمة المراقبة و اإلنذار المبكر القادر ة
ر المؤش )
حسنة والتعاون عي القطاعات وبين 1.D2)؛ مستويات استجابة الصحة العمومية الوطنية والمتوسطة
ُ
وقنوات االتصال الم
العامة واألمن الصح والمحلية فيما يتعلق بمراقبة األحداث ذات األهمية للصحة
ي
ر )المؤش
ن 2.D2)؛ القدرة عىل
وتحسي تحليل
ن البيانات عىل المستوى المتوسط والوطت ي
ر )المؤش
رش 3.D2 .)باإلضافة إل وع
الدول تنفيذ و
ي
ن
ف عرض مهام ووظائف المراقبة
القائمة عىل األحداث إذ ، اللوائح الصحية
ي
درجات التقييم المشي ك وإحراز تقدم نحو تلبية المتطلبات المبينة ف ن
ي
ستضمن زيادة ف ن
الدولية
.
تحسين أيضا، تنفيذ المراقبة المتكاملة لألمراض واالستجابة لها، وذلك بالنسبة
ي
ن
تعد هذه الوثيقة مكملة ويمكن أن تساعد ف ل لدول
ا
ي
االتحاد األفريق
ي
ن
اعتمدت االسي األعضاء ف اتيجية المتكاملة لمراقبة األمراض واالستجابة لها،
لت عىل وجه الخصوص ي
بالنسبة
للطبعة الثالثة ) 2019 تتضمن أجزاء حول
( الت المراقبة القائمة عىل األحداث ي
.
more
This report describes the activities of the WHO European Centre for Primary Health Care in 2022.The Centre accelerated face-to-face country support after the wake of the COVID-19 pandemic to support countries in engaging in analysis and diagnosis, developing strategies and policies, building capacit...y and tracking implementation progress and impact. The Centre delivered intensive support in the countries of the Universal Health Coverage Partnership. The Centre continued to develop policy guidance, publish good practices, have capacity-building activities and policy dialogues and solidified its signature product Let’s Talk Primary Health Care talk show platform. The highlight of 2022 was the launch of two WHO Primary Health Care Demonstration Platforms to facilitate cross-country experience exchange.
more
Website last accessed on 09.04.2023
Youtube Video - Documentário Doença de Chagas
Website last accessed on 09.04.2023
Donors making a difference: Eliminating neglected tropical diseases and other outbreaks (Websites WHO 14. June 2022)
Driving progress towards rabies elimination: Results of Gavi’s Learning Agenda on rabies and new WHO position on rabies immunization
Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. It is a significant public health problem, affecting millions of people worldwide. And although it was described 110 years ago, only two old nitroheterocyclic drugs, benznidazole and nifurtimox, are cu...rrently available for the treatment of Chagas disease and both have several limitations. Besides the clear unmet medical need, many challenges preclude the development of new treatments, some of them related to a lack of understanding of the pathophysiology of the disease and parasite-host interactions. New knowledge and tools are becoming available, but the number of new chemical entities progressing through the preclinical pipeline is inadequate. Therefore, it is still uncertain whether safe, effective and accessible new drugs will be available in the near future. The Chagas disease research community must commit to even greater collaboration to ensure that patients eventually benefit from better treatments.
more
Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT... has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host−parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.
more
Website last accessed on 10.04.2023
The Chagas disease is frequently referred to as the effects that the parasite Trypanosoma cruzi (T. cruzi) has on people’s health. However, from our perspective, Chagas is much more than that: it is a complex socioenvironmental health problem in which elemen...ts of different nature converge and interact. The biomedical and epidemiological aspects, which are most frequently addressed, are only a piece of the puzzle that needs to be complete in order to understand Chagas in all its complexity. Social, environmental, economic, political, cultural, and educational elements turn out to be essential in comprehending the magnitude of the problem without prejudice or stigmatizations.
more
Preventive chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis control. However, a single dose of PZQ (40 mg/kg) does not cure all infections. Repeated doses of PZQ at short intervals might increase efficacy in terms of cure rate (CR) and intensity reduction rate (IRR). Here, ...we determined the efficacy of a single versus four repeated treatments with PZQ on Schistosoma mansoni infection in school-aged children from Côte d'Ivoire, using two different diagnostic tests.
more
Website last accessed on 10.04.2023
Investing to overcome the global impact of neglected tropical diseases charts new ground in tackling the 17 neglected tropical diseases (NTDs) that aff ect more than a billion people in 149 countries worldwide. It makes the case for domestic investment to reach the targets of WHO’s Roadmap on NTDs... by 2020 and sustain enhanced, equitable access to high-quality coverage against these diseases to 2030.
Th is third WHO report anticipates the investments needed as countries graduate from
low-income to middle-income status and as the world’s focus expands from the Millennium Development Goals to the Sustainable Development Goals.
more
Website last accessed on 10.04.2023
Accessed on 10.04.2023
While virtually unheard of in developed countries, NTDs are a group of medically diverse parasitic and bacterial infectious diseases common in tropical and subtropical areas. NTDs affect more than 1.5 billion people annually, causing death, blindness, disfigurement, chroni...c pain, cognitive impairment and other long-term disabilities that create obstacles to education, employment, economic growth and overall
development. When measured in disability-adjusted life years (DALYs), the NTD burden is greater than malaria or tuberculosis.
more
The Pharmaceutical Forum of the Americas (PFA) has previously published guidelines and organised campaigns for community pharmacists on the prevention, detection and control of arbovirus infections in 2018 with a grant from the FIP Foundation for Pharmacy Education and Research. Building on that exp...ertise, FIP joined efforts with the PFA and is now publishing its first-ever handbook to support pharmacists in the
area of vector-borne diseases. As the integration of the regional forums in FIP advances, such collaborative projects are tangible results of an increasingly regionally informed and regionally targeted work by FIP.
more
Accessed on 10.04.2023
Information sheet - Diarrhoea control with ORS and Zink
This report includes six case studies from 12 individuals with lived experience of diverse health conditions. These case studies explore the topics of power dynamics and power reorientation towards individuals with lived experience; informed decision-making and health literacy; community engagement ...across broader health networks and health systems; lived experience as evidence and expertise; exclusion and the importance of involving groups that are marginalized; and advocacy and human rights.
It is the first publication in the WHO Intention to action series, which aims to enhance the limited evidence base on the impact of meaningful engagement and address the lack of standardized approaches on how to operationalise meaningful engagement. The Intention to action series aims to do this by providing a platform from which individuals with lived experience, and organizational and institutional champions, can share solutions, challenges and promising practices related to this cross-cutting agenda. The Intention to action series also aims to provide powerful narratives,inspiration and evidence towards the Fourth United Nations High Level Meeting on NCDs in 2025 and achieving the 2030 United Nations Sustainable Development Goals (SDGs).
more
Il s’agit du premier rapport d’une collection de l’OMS intitulée De l’intention à l’action, qui vise à renforcer la base de données probantes sur l’impact de la participation significative et à combler le manque d’approches normalisées pour permettre la participation significativ...e fonctionnelle. À cette fin, la collection De l’intention à l’action a été pensée comme plateforme pour que les personnes avec une expérience vécue ainsi que les organisations et institutions à la pointe sur ces questions puissent échanger sur les solutions, les difficultés et les pratiques prometteuses relatives à cet objectif transversal. Elle vise également à fournir des récits et des modèles puissants, ainsi que des données probantes dans la perspective de la quatrième réunion publique de haut niveau des Nations Unies sur les MNT, qui devrait se tenir en 2025, et en vue d’atteindre les objectifs de développement durable (ODD) à l’horizon 2030.
À cette fin, le présent rapport comprend six études de cas impliquant douze personnes avec une expérience vécue d’affections diverses. Ces études de cas analysent les dynamiques de pouvoir et la réorientation des pouvoirs en faveur des individus avec une expérience vécue, la prise de décision éclairée et les connaissances en matière de santé, la participation communautaire à l’échelle des réseaux et des systèmes de santé globaux, l’expérience vécue comme donnée probante et expertise, l’exclusion et l’importance de la participation des groupes qui sont marginalisés, ainsi que la défense d’une cause et les droits humains.
more
Este informe es el primero de la serie «Intención de pasar a la acción» de la OMS, cuyo objetivo es mejorar la limitada base de evidencia sobre la repercusión de la participación constructiva y abordar la falta de enfoques normalizados sobre cómo hacer operativa dicha participación. La serie... «Intención de pasar a la acción» pretende conseguirlo proporcionando una plataforma desde la que personas con experiencias vividas, y defensores de organizaciones e instituciones, puedan compartir soluciones, dificultades y prácticas prometedoras relacionadas con esta agenda transversal. Esta serie también tiene como objetivo proporcionar poderosas historias, inspiración y evidencia de cara a la Cuarta Reunión de Alto Nivel de las Naciones Unidas sobre las ENT que se celebrará en 2025, así como lograr los Objetivos de Desarrollo Sostenible (ODS) de las Naciones Unidas para 2030.
Para ello, este informe incluye seis estudios de casos procedentes de 12 personas con experiencias vividas de diversas dolencias. Se analizan temas como la dinámica del poder y la reorientación del poder hacia las personas con experiencias vividas; la toma de decisiones informada y la alfabetización sanitaria; la implicación de la comunidad en redes sanitarias y sistemas de salud más amplios; la experiencia vivida como evidencia y conocimientos; la exclusión y la importancia de implicar a los grupos que están marginados; y la promoción y los derechos humanos
more
HIV, viral hepatitis and STI epidemics, particularly among people who inject drugs and other key populations, continue to be fuelled by laws and policies criminalizing sex work; drug use or possession; diverse forms of gender expression and sexuality; stigma and discrimination; gender discrimination...; violence; lack of community empowerment and other violations of human rights. These sociostructural factors limit access to health services, constrain how these services are
delivered and diminish their effectiveness.
more
L'OMS est un partenaire de confiance du Gouvernement du Niger depuis 1960. En tant que conseiller principal du gouvernement en matière de santé publique et présente dans toutes les régions du pays, l'OMS apporte un soutien technique et financier de qualité et bien coordonné dans le cadre des S...tratégies de Coopération convenues entre l'OMS et le gouvernement du Niger en fonction des priorités définies dans les différents politiques et programmes nationaux. La contribution de l’OMS s’inscrit également dans le cadre du Plan-cadre de Coopération des Nations Unies avec le Niger et des ODD au niveau mondial.
more